pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

AUGUST 16, 2021

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. Lilly is also running the Adhere trial of lebrikizumab in combination with topical corticosteroids, which should generate results in the coming months. Lilly shelled out $1.1

Antibody 52

Antibody Trials Marketing Drugs 52

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52

pharmaphorum

JANUARY 6, 2023

Meanwhile, ACELYRIN is due to accelerate its development of izokibep in patients with moderate-to-severe Hidradenitis Suppurativa (HS), following a 30-patient open-label Part A of a phase 2b/3 trial, the top-line 12-week data from which found that izokibep achieves higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR).

Trials 59

Trials Marketing Protein Antibody 59

The Pharma Data

AUGUST 1, 2021

Saphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus . The Phase III trial in SLE using subcutaneous delivery has been initiated and additional Phase III trials are planned for lupus nephritis, cutaneous lupus erythematosus and myositis.

Trials 52

Trials Clinical Development Antibody Dermatology 52

pharmaphorum

AUGUST 24, 2021

Analysts at Jefferies think that Bimzelx’ profile could drive it to sales of more than $2 billion a year, assuming it also gets approved in follow-up indications psoriatic arthritis and ankylosing spondylitis. For now though, the drugmaker is going it alone.

Sales 52

Sales Marketing Drugs Antibody 52

pharmaphorum

APRIL 26, 2021

The IL-17A and IL-17F inhibitor hit all its objectives in the phase 2 trial, which has now been published in The Lancet, and showed that it was significantly more effective than placebo at clearing up skin lesions in patients with moderate to severe plaque psoriasis. billion in sales last year.

Antibody 52

Antibody Drugs Marketing Licensing 52

The Pharma Data

NOVEMBER 8, 2020

9, 2020 /PRNewswire/ — Solid 9M business performance despite COVID-19 and generic Aczone challenges: Net Sales €613.8 Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. BARCELONA, Spain , Nov.

Dermatology 52

Dermatology Sales Marketing Production 52

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. In contrast, several drugs experienced sale declines, such as Remicade (infliximab), an old immunology medication that continues to decline due to the rise of biosimilars since 2016.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

MAY 4, 2021

The announcement comes a few days after Merck KGaA’s development partner Avillion announced supportive results in a phase 2 psoriasis trial. German Merck also received an undisclosed milestone payment and will be eligible for development and commercial milestone payments as well as “industry standard” royalties on net sales.

Licensing 52

Licensing Licensing Dermatology Antibody 52

The Pharma Data

JULY 8, 2021

Tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population across Phase II and III clinical trials. The BLA was based on results from the PATHFINDER clinical trials programme, including results from the pivotal NAVIGATOR Phase III trial.

Trials 52

Trials Medicine Sales Clinical Trials 52

The Pharma Data

OCTOBER 9, 2021

Tezepelumab Tezepelumab is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades. In EoE, a Phase III trial is planned.

Drugs 52

Drugs Sales Medicine Dermatology 52

The Pharma Data

SEPTEMBER 15, 2020

On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC). A Phase 3 trial is ongoing. Protease Inhibitor Program.

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52